Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Arixtra
2. Fondaparinux
3. Quixidar
1. 114870-03-0
2. Arixtra
3. Quixidar
4. Fondaparin Sodium
5. Sr-90107a
6. Org 31540
7. Sr 90107a
8. Fondaparinux Sodium For Assay
9. Org-31540
10. Fondaparinux Sodium Identification
11. X0q6n9usoz
12. Ic-851589
13. Xantidar
14. Arixtra (tn)
15. Unii-x0q6n9usoz
16. Fondaparinux Sodium [usan]
17. Fondaparinux Sodium [usan:inn:ban]
18. Gsk-576428
19. Ic 85158
20. Sr-90107
21. Chembl1200644
22. Fondaparinux Sodium [mi]
23. Fondaparinux Sodium [inn]
24. Fondaparinux Sodium [jan]
25. Dtxsid501027612
26. Fondaparinux Sodium [mart.]
27. Fondaparinux Sodium (jan/usp/inn)
28. Fondaparinux Sodium [usp-rs]
29. Fondaparinux Sodium [who-dd]
30. Natural Heparin Pentasaccharide Sodium
31. Akos005146286
32. Fondaparinux Sodium [ema Epar]
33. Ccg-270693
34. Fondaparinux Sodium [orange Book]
35. As-80003
36. Fondaparinux Sodium [usp Monograph]
37. C71476
38. D01844
39. A803253
40. Q421218
41. Alpha-d-glucopyranoside, Methyl O-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-beta-d-glucopyranuronosyl(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-l-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen Sulfate), Decasodium Salt
42. Decasodium 6-[6-[2-carboxylato-4-hydroxy-6-[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)tetrahydropyran-3-yl]oxy-5-sulfonatooxy-tetrahydropyran-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)tetrahydropyran-3-yl]oxy-3-[4;fondaparinux Sodium
43. Methly O-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-beta-d-glucopyranuronosyl-(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-l-idopyranuronosyl-(1-4)-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranoside, Decasodium Salt
Molecular Weight | 1728.1 g/mol |
---|---|
Molecular Formula | C31H43N3Na10O49S8 |
Hydrogen Bond Donor Count | 9 |
Hydrogen Bond Acceptor Count | 52 |
Rotatable Bond Count | 20 |
Exact Mass | 1726.7707769 g/mol |
Monoisotopic Mass | 1726.7707769 g/mol |
Topological Polar Surface Area | 901 Ų |
Heavy Atom Count | 101 |
Formal Charge | 0 |
Complexity | 3330 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 25 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 11 |
1 of 4 | |
---|---|
Drug Name | Arixtra |
Drug Label | ARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1... |
Active Ingredient | Fondaparinux sodium |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 5mg/0.4ml; 2.5mg/0.5ml; 7.5mg/0.6ml; 10mg/0.8ml |
Market Status | Prescription |
Company | Agi |
2 of 4 | |
---|---|
Drug Name | Fondaparinux sodium |
PubMed Health | Fondaparinux (Injection) |
Drug Classes | Anticoagulant |
Drug Label | ARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1... |
Active Ingredient | Fondaparinux sodium |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 2.5mg/0.5ml; 7.5mg/0.6ml; 5mg/0.4ml; 10mg/0.8ml |
Market Status | Prescription |
Company | Dr Reddys Labs |
3 of 4 | |
---|---|
Drug Name | Arixtra |
Drug Label | ARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1... |
Active Ingredient | Fondaparinux sodium |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 5mg/0.4ml; 2.5mg/0.5ml; 7.5mg/0.6ml; 10mg/0.8ml |
Market Status | Prescription |
Company | Agi |
4 of 4 | |
---|---|
Drug Name | Fondaparinux sodium |
PubMed Health | Fondaparinux (Injection) |
Drug Classes | Anticoagulant |
Drug Label | ARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1... |
Active Ingredient | Fondaparinux sodium |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 2.5mg/0.5ml; 7.5mg/0.6ml; 5mg/0.4ml; 10mg/0.8ml |
Market Status | Prescription |
Company | Dr Reddys Labs |
* 1. 5-mg/0. 3-ml and 2. 5-mg/0. 5-ml solution for injection:
Prevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.
Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.
Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.
Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.
* 2. 5-mg/0. 5-ml solution for injection:
Treatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.
infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
* 5-mg/0. 4-ml, 7. 5-mg/0. 6-ml and 10-mg/0. 8-ml solution for injection:
Treatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.
1. 5 mg/0. 3 ml and 2. 5 mg/0. 5 ml, solution for injection:
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5. 1).
Prevention of Venous Thromboembolic Events (VTE) in medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.
2. 5 mg/0. 5 ml, solution for injection:
Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated (see sections 4. 4 and 5. 1).
Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
5 mg/0. 4 ml, 7. 5 mg/0. 6 ml and 10 mg/0. 8 ml solution for injection:
Treatment of acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.
Factor Xa Inhibitors
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. (See all compounds classified as Factor Xa Inhibitors.)
B01AX05
B01AX05
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
95
PharmaCompass offers a list of Fondaparinux Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fondaparinux Sodium manufacturer or Fondaparinux Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fondaparinux Sodium manufacturer or Fondaparinux Sodium supplier.
PharmaCompass also assists you with knowing the Fondaparinux Sodium API Price utilized in the formulation of products. Fondaparinux Sodium API Price is not always fixed or binding as the Fondaparinux Sodium Price is obtained through a variety of data sources. The Fondaparinux Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fondaparinux manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fondaparinux, including repackagers and relabelers. The FDA regulates Fondaparinux manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fondaparinux API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fondaparinux manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fondaparinux supplier is an individual or a company that provides Fondaparinux active pharmaceutical ingredient (API) or Fondaparinux finished formulations upon request. The Fondaparinux suppliers may include Fondaparinux API manufacturers, exporters, distributors and traders.
click here to find a list of Fondaparinux suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fondaparinux DMF (Drug Master File) is a document detailing the whole manufacturing process of Fondaparinux active pharmaceutical ingredient (API) in detail. Different forms of Fondaparinux DMFs exist exist since differing nations have different regulations, such as Fondaparinux USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fondaparinux DMF submitted to regulatory agencies in the US is known as a USDMF. Fondaparinux USDMF includes data on Fondaparinux's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fondaparinux USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fondaparinux suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Fondaparinux Drug Master File in Korea (Fondaparinux KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Fondaparinux. The MFDS reviews the Fondaparinux KDMF as part of the drug registration process and uses the information provided in the Fondaparinux KDMF to evaluate the safety and efficacy of the drug.
After submitting a Fondaparinux KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Fondaparinux API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Fondaparinux suppliers with KDMF on PharmaCompass.
A Fondaparinux written confirmation (Fondaparinux WC) is an official document issued by a regulatory agency to a Fondaparinux manufacturer, verifying that the manufacturing facility of a Fondaparinux active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Fondaparinux APIs or Fondaparinux finished pharmaceutical products to another nation, regulatory agencies frequently require a Fondaparinux WC (written confirmation) as part of the regulatory process.
click here to find a list of Fondaparinux suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fondaparinux as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fondaparinux API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fondaparinux as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fondaparinux and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fondaparinux NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fondaparinux suppliers with NDC on PharmaCompass.
Fondaparinux Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fondaparinux GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fondaparinux GMP manufacturer or Fondaparinux GMP API supplier for your needs.
A Fondaparinux CoA (Certificate of Analysis) is a formal document that attests to Fondaparinux's compliance with Fondaparinux specifications and serves as a tool for batch-level quality control.
Fondaparinux CoA mostly includes findings from lab analyses of a specific batch. For each Fondaparinux CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fondaparinux may be tested according to a variety of international standards, such as European Pharmacopoeia (Fondaparinux EP), Fondaparinux JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fondaparinux USP).